Saegis Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Saegis Pharmaceuticals Inc. hopes to be the first to market with therapies for mild cognitive impairment and age-related cognitive decline. Through a combination of in-licensing and internal drug development, it also plans to attack cognitive impairment related to stroke, brain trauma, and other neurological disorders.